Current Diabetes Reports

, Volume 10, Issue 5, pp 370–379

Immune Intervention in Children with Type 1 Diabetes

  • Johnny Ludvigsson
  • for The Linköping Diabetes Immune Intervention study group

DOI: 10.1007/s11892-010-0138-y

Cite this article as:
Ludvigsson, J. & for The Linköping Diabetes Immune Intervention study group Curr Diab Rep (2010) 10: 370. doi:10.1007/s11892-010-0138-y


Not only T cells but also B cells play a role in the autoimmune process. Both monoclonal antiCD3 and antiCD20 antibodies seem efficacious. However, such treatments need to be refined to minimize adverse events. Use of autoantigens to create tolerance is a concept with great potential. GAD65 treatment has shown efficacy without adverse events thus far, and administration of the insulin B chain shows interesting immunologic effects. Other more or less speculative approaches to modulate the immune process need further studies with good design. Risks that are too serious cannot be motivated. In addition, as the β cells may die even though the autoimmune process is stopped, protective measures may be valuable (eg, active insulin treatment, and perhaps interleukin-1 receptor antagonists to reduce the nonautoimmune inflammation). Combination of immune intervention, protection of the β cells, and stimulation of regeneration may lead to a milder disease or even a cure in the future, and prevention is no longer unrealistic.


Type 1 diabetesImmune interventionAntiCD3AntiCD20GAD65AutoantigensVitamin Dβ-Cell regenerationChildren

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Johnny Ludvigsson
    • 1
  • for The Linköping Diabetes Immune Intervention study group
  1. 1.Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health SciencesLinköping UniversityLinköpingSweden